Wild type p53-dependent transcriptional upregulation of cathepsin L expression is mediated by C/EBPα in human glioblastoma cells

Biological Chemistry

Volumn 391, Issue 9, 2010, Pages 1031-1040

  Katara, Rahul ^a   Mir, Riyaz A ^a   Shukla, Abhay A ^a   Tiwari, Ashutosh ^a   Singh, Neelima ^b   Chauhan, Shyam S ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b G R MEDICAL COLLEGE   (India)

Author keywords

C EBP ; cathepsin L; ChIP assays; p53; promoter; real time PCR; transcription

Indexed keywords

CATHEPSIN L; CYSTATIN C; MESSENGER RNA; PROTEIN P53; TRANSCRIPTION FACTOR;

ARTICLE; CHROMATIN IMMUNOPRECIPITATION; ENZYME ASSAY; GLIOBLASTOMA; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SITE DIRECTED MUTAGENESIS; TRANSCRIPTION REGULATION; TUMOR CELL; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

CATHEPSIN L; CCAAT-ENHANCER-BINDING PROTEINS; GLIOBLASTOMA; HUMANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 77957574050     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2010.103     Document Type: Article

References (59)

1. Agarwal, M.L., Agarwal, A., Taylor, W.R., and Stark, G.R. (1995). p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc. Natl. Acad. Sci. USA 92, 8493-8497.
2. Agarwal, M.L., Agarwal, A., Taylor, W.R., Chernova, O., Sharma, Y., and Stark, G.R. (1998). A p53-dependent S-phase checkpoint helps to protect cells from DNA damage in response to starvation for pyrimidine nucleotides. Proc. Natl. Acad. Sci. USA 95, 14775-14780.
3. Arora, S. and Chauhan, S.S. (2002). Identification and characterization of a novel human cathepsin L splice variant. Gene 293, 123-131.
4. Badie, B., Goh, C.S., Klaver, J., Herweijer, H., and Boothman, D.A. (1999). Combined radiation and p53 gene therapy of malignant glioma cells. Cancer Gene Ther. 6, 155-162.
5. Bakhshi, R., Goel, A., Seth, P., Chhikara, P., and Chauhan, S.S. (2001). Cloning and characterization of human cathepsin L promoter. Gene 275, 93-101.
6. Baricos, W.H., Cortez, S.L., Le, Q.C., Wu, L.T., Shaw, E., Hanada, K., and Shah, S.V. (1991). Evidence suggesting a role for cathepsin L in an experimental model of glomerulonephritis. Arch. Biochem. Biophys. 288, 468-472.
7. Benavides, F., Venables, A., Poetschke Klug, H., Glasscock, E., Rudensky, A., Gomez, M., Martin Palenzuela, N., Guenet, J.L., Richie, E.R., and Conti, CJ. (2001). The CD4 T cell-deficient mouse mutation nackt (nkt) involves a deletion in the cathepsin L (CtsI) gene. Immunogenetics 53, 233-242.
8. Bhana, S. and Lloyd, D.R. (2008). The role of p53 in DNA damagemediated cytotoxicity overrides its ability to regulate nucleotide excision repair in human fibroblasts. Mutagenesis 23, 43-50.
9. Bian, J. and Sun, Y. (1997). Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. Mol. Cell. Biol. 17, 6330-6338.
10. Chapman, H.A., Riese, RJ., and Shi, G.P. (1997). Emerging roles for cysteine proteases in human biology Annu. Rev. Physiol. 59, 63-88.
11. Chauhan, S.S., Goldstein, LJ., and Gottesman, M.M. (1991). Expression of cathepsin L in human tumors. Cancer Res. 51, 1478-1481.
12. Chauhan, S.S., Ray, D., Kane, S.E., Willingham, M.C., and Gottesman, M.M. (1998). Involvement of carboxy-terminal amino acids in secretion of human lysosomal protease cathepsin L. Biochemistry 37, 8584-8594.
13. Cunnane, G., FitzGerald, O., Hummel, K.M., Gay, R.E., Gay, S., and Bresnihan, B. (1999). Collagenase, cathepsin B and cathepsin L gene expression in the synovial membrane of patients with early inflammatory arthritis. Rheumatology (Oxford) 38, 34-42.
14. Delaisse, J.M. and Vaes, G. (1992). Biology and Physiology of the Osteoclast. B.R. Rafkin and C.Y. Gay, eds. (Boca Raton, FL, USA: CRC Press).
15. El-Deiry, W.S., Kern, S.E., Pietenpol, J.A., Kinzler, K.W., and Vogelstein, B. (1992). Definition of a consensus binding site for p53. Nat Genet. 1, 45-49.
16. Erickson-Lawrence, M., Zabludoff, S.D., and Wright, W.W. (1991). Cyclic protein-2, a secretory product of rat Sertoli cells, is the proenzyme form of cathepsin L. Mol. Endocrinol. 5, 1789-1798.
17. Farmer, G., Bargonetti, J., Zhu, H., Friedman, P., Prywes, R., and Prives, C. (1992). Wild-type p53 activates transcription in vitro. Nature 358, 83-86.
18. Felbor, U., Kessler, B., Mothes, W., Goebel, H.H., Ploegh, H.L., Bronson, R.T., and Olsen, B.R. (2002). Neuronal loss and brain atrophy in mice lacking cathepsins B and L. Proc. Natl. Acad. Sci. USA 99, 7883-7888.
19. Frade, R. (1999). Structure and functions of proteases which cleave human C3 and are expressed on normal or tumor human cells: some are involved in tumorigenic and metastatic properties of human melanoma cells. Immunopharmacology 42, 39-45.
20. Fulci, G., Labuhn, M., Maier, D., Lachat, Y., Hausmann, O., Hegi, M.E., Janzer, R.C., Merlo, A., and Van Meir, E.G. (2000). p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma. Oncogene 19, 3816-3822.
21. Funk, W.D., Pak, D.T., Karas, R.H., Wright, W.E., and Shay, J.W (1992). A transcriptionally active DNA-binding site for human p53 protein complexes. Mol. Cell. Biol. 12, 2866-2871.
22. Gacko, M. and Glowinski, S. (1998). Cathepsin D and cathepsin L activities in aortic aneurysm wall and parietal thrombus. Clin. Chem. Lab. Med. 36, 449-452.
23. Gocheva, V. and Joyce, J.A. (2007). Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 6, 60-64.
24. Hainaut, P. and Hollstein, M. (2000). p53 and human cancer: the first ten thousand mutations. Adv. Cancer Res. 77, 81-137.
25. Harris, C.C. (1995). Deichmann Lecture-p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology and cancer risk assessment. Toxicol. Lett. 82-83, 1-7.
26. Ito, H., Kanzawa, T., Miyoshi, T., Hirohata, S., Kyo, S., Iwamaru, A., Aoki, H., Kondo, Y., and Kondo, S. (2005). Therapeutic efficacy of PUMA for malignant glioma cells regardless of p53 status. Hum. Gene. Ther. 16, 685-698.
27. Jean, D., Guillaume, N., and Frade, R. (2002). Characterization of human cathepsin L promoter and identification of binding sites for NF-Y, Sp1 and Sp3 that are essential for its activity Biochem. J. 361, 173-184.
28. Jean, D., Rousselet, N., and Frade, R. (2006). Expression ofcathep-sin L in human tumor cells is under the control of distinct reg-ulatory mechanisms. Oncogene 25, 1474-1484.
29. Kang, X., Xiao, X., Harata, M., Bai, Y., Nakazaki, Y., Soda, Y., Kurita, R., Tanaka, T., Komine, F., Izawa, K., et al. (2006). Anti-angiogenic activity ofBAI1 in vivo: implications for gene ther-apy of human glioblastomas. Cancer Gene Ther. 13, 385-392.
30. Katunuma, N., Matsunaga, Y., Matsui, A., Kakegawa, H., Endo, K., Inubushi, T., Saibara, T., Ohba, Y., and Kakiuchi, T. (1998). Novel physiological functions of cathepsins B and L on antigen processing and osteoclastic bone resorption. Adv. Enzyme Regul. 38, 235-251.
31. Kern, S.E., Pietenpol, J.A., Thiagalingam, S., Seymour, A., Kinzler, K.W., and Vogelstein, B. (1992). Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256, 827-830.
32. Ko, LJ. and Prives, C. (1996). p53: puzzle and paradigm. Genes Dev. 10, 1054-1072.
33. Lah, T.T., Strojnik, T., Levicar, N., Bervar, A., Zajc, I., Pilkington, G., and Kos, J. (2000). Clinical and experimental studies ofcys-teine cathepsins and their inhibitors in human brain tumors. Int. J. Biol. Markers 15, 90-93.
34. Lankelma, J.M., Voorend, D.M., Barwari, T., Koetsveld, J., Van der Spek, A.H., De Porto, A.P., Van Rooijen, G., and Van Noorden, CJ. (2010). Cathepsin L, target in cancer treatment? Life Sci. 86, 225-233.
35. Levicar, N., Dewey, R.A., Daley, E., Bates, T.E., Davies, D., Kos, J., Pilkington, GJ., and Lah, T.T. (2003). Selective suppression of cathepsin L by antisense cDNA impairs human brain tumor cell invasion in vitro and promotes apoptosis. Cancer Gene Ther. 10, 141-151.
36. Li, W., Dalen, H., Eaton, J.W., and Yuan, X.M. (2001). Apoptotic death of inflammatory cells in human atheroma. Arterioscler. Thromb. Vasc. Biol. 21, 1124-1130.
37. Liu, J., Zhan, M., Hannay, J.A., Das, P., Bolshakov, S.V., Kotilin-gam, D., Yu, D., Lazar, A.F., Pollock, R.E., and Lev, D. (2006). Wild-type p53 inhibits nuclear factor-κB-induced matrix metal-loproteinase-9 promoter activation: implications for soft tissue sarcoma growth and metastasis. Mol. Cancer Res. 4, 803-810.
38. Ludes-Meyers, J.H., Subler, M.A., Shivakumar, C.V., Munoz, R.M., Jiang, P., Bigger, J.E., Brown, D.R., Deb, S.P., and Deb, S. (1996). Transcriptional activation of the human epidermal growth factor receptor promoter by human p53. Mol. Cell. Biol. 16, 6009-6019.
39. Maciewicz, R.A., Wotton, S.F., Etherington, DJ., and Duance, V.C. (1990). Susceptibility of the cartilage collagens types II, IX and XI to degradation by the cysteine proteinases, cathepsins B and L. FEBS Lett. 269, 189-193.
40. Marutani, M., Tonoki, H., Tada, M., Takahashi, M., Kashiwazaki, H., Hida, Y., Hamada, J., Asaka, M., and Moriuchi, T. (1999). Dominant-negative mutations of the tumor suppressor p53 relat-ing to early onset of glioblastoma multiforme. Cancer Res. 59, 4765-4769.
41. Marx, J.L. (1987). A new wave of enzymes for cleaving prohor-mones. Science 235, 285-286.
42. Meng, R.D., McDonald, E.R., Sheikh, M.S., Fornace, A.J. Jr., and El-Deiry, W.S. (2000). The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpres-sion and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis. Mol. Ther. 1, 130-144.
43. Milner, J. and Medcalf, E.A. (1991). Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 65, 765-774.
44. Pilkington, GJ. (1994). Tumour cell migration in the central nerv-ous system. Brain Pathol. 4 157-166.
45. Rolley, N., Butcher, S., and Milner, J. (1995). Specific DNA binding by different classes of human p53 mutants. Oncogene 11, 763-770.
46. Rousselet, N., Mills, L., Jean, D., Tellez, C., Bar-Eli, M., and Frade, R. (2004). Inhibition of tumorigenicity and metastasis of human melanoma cells by anti-cathepsin L single chain variable frag-ment. Cancer Res. 64, 146-151.
47. Russell, S.J., Ye, Y.W., Waber, P.G., Shuford, M., Schold, S.C. Jr., and Nisen, P.D. (1995). p53 mutations, O6-alkylguanine DNA alkyltransferase activity, and sensitivity to procarbazine in human brain tumors. Cancer 75, 1339-1342.
48. Seth, P., Mahajan, V.S., and Chauhan, S.S. (2003). Transcription of human cathepsin L mRNA species hCATL B from a novel alter-native promoter in the first intron of its gene. Gene 321, 83-91.
49. Sheikh, M.S., Huang, Y., Fernandez-Salas, E.A., El-Deiry, W.S., Friess, H., Amundson, S., Yin, J., Meltzer, S.J., Holbrook, N.J., and Fornace, AJ. Jr. (1999). The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointes-tinal tract. Oncogene 18, 4153-4159.
50. Shuja, S. and Murnane, MJ. (1996). Marked increases in cathepsin B and L activities distinguish papillary carcinoma of the thyroid from normal thyroid or thyroid with non-neoplastic disease. Int. J. Cancer 66, 420-426.
51. Sivaparvathi, M., Yamamoto, M., Nicolson, G.L., Gokaslan, Z.L., Fuller, G.N., Liotta, L.A., Sawaya, R., and Rao, J.S. (1996). Expression and immunohistochemical localization of cathepsin L during the progression of human gliomas. Clin. Exp. Metastas. 14, 27-34.
52. Sun, Y., Wicha, M., and Leopold, W.R. (1999). Regulation ofmetas-tasis-related gene expression by p53: a potential clinical impli-cation. Mol. Carcinog. 24, 25-28.
53. Tada, M., Matsumoto, R., Iggo, R.D., Onimaru, R., Shirato, H., Sawamura, Y., and Shinohe, Y. (1998). Selective sensitivity to radiation of cerebral glioblastomas harboring p53 mutations. Cancer Res. 58, 1793-1797.
54. Tobin, DJ., Foitzik, K., Reinheckel, T., Mecklenburg, L., Botch-karev, V.A., Peters, C., and Paus, R. (2002). The lysosomal pro-tease cathepsin L is an important regulator of keratinocyte and melanocyte differentiation during hair follicle morphogenesis and cycling. Am. J. Pathol. 160, 1807-1821.
55. Towbin, H., Staehelin, T., and Gordon, J. (1979). Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA 76, 4350-4354.
56. Willis, A., Jung, EJ., Wakefield, T., and Chen, X. (2004). Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene 23, 2330-2338.
57. Wu, G.S., Saftig, P., Peters, C., and El-Deiry, W.S. (1998). Potential role for cathepsin D in p53-dependent tumor suppression and chemo sensitivity Oncogene 16, 2177-2183.
58. Yoon, K. and Smart, R.C. (2004). C/EBPα is a DNA damage-induc-ible p53-regulated mediator of the G1 checkpoint in keratino-cytes. Mol. Cell. Biol. 24, 10650-10660.
59. Zhu, D.M. and Uckun, F.M. (2000). Z-Phe-Gly-NHO-Bz, an inhib-itor of cysteine cathepsins, induces apoptosis in human cancer cells. Clin. Cancer Res. 6, 2064-2069.